Rocket Pharmaceuticals (RCKT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 54/100 (HIGH), 15.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.17% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
- Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
- Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
- Rocket receives $150m credit facility to advance cardiovascular portfolio
- Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
- Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
- Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
- Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study. — Clin Pharmacol Ther 2026 Sep 6 PMID 42702729
- Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial. — JAMA 2026 Aug 29 PMID 42667613
- MicroRNAs as novel therapeutics against multidrug-resistant ESKAPE pathogens: mechanisms, challenges, and future directions. — Gene 2026 Dec 5 PMID 42648582
- The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. — J Card Fail 2026 Aug 20 PMID 42624353
- Crisis readiness for rare disease populations: learnings and recommendations by the European Reference Networks. — Lancet Reg Health Eur 2026 Oct PMID 42604059
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Rocket Pharmaceuticals.
Full RCKT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.